ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SAGE Sage Therapeutics Inc

13.28
-0.66 (-4.73%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sage Therapeutics Inc NASDAQ:SAGE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.66 -4.73% 13.28 12.89 14.41 14.56 13.19 14.11 1,516,090 00:13:19

Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019

11/07/2019 11:30am

Business Wire


Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sage Therapeutics Charts.

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m. EDT to report its second quarter 2019 financial results and discuss recent business updates.

The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage’s portfolio of novel compounds targets critical receptor systems in the brain and includes the first treatment specifically approved by the U.S. Food and Drug Administration for postpartum depression as well as compounds being developed as potential treatments for diseases such as major depressive disorder, insomnia, bipolar disorder and essential tremor. For more information, please visit www.sagerx.com.

Investor Contact Maren Killackey 617-949-4113 maren.killackey@sagerx.com

Media Contact Alexis Smith 617-588-3740 alexis.smith@sagerx.com

1 Year Sage Therapeutics Chart

1 Year Sage Therapeutics Chart

1 Month Sage Therapeutics Chart

1 Month Sage Therapeutics Chart

Your Recent History

Delayed Upgrade Clock